A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.

Researchers here described how they were able to safely and ethically enroll adolescents in a landmark trial of a drug that ...

HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...

A patient told MassLive she was horrified to receive a phone call from her surgeon post-operation saying she should be tested for bloodborne pathogens.

Without urgent intervention, Kenya risks a surge in new HIV infections, which currently stand at 16,752 annually, NSDCC said.

Prominent gaps in pediatric and adolescent HIV care translate into priorities that need to be addressed for optimizing care ...